TGA recalls four more batches of Clexane
This article was originally published in Scrip
Australia's Therapeutic Goods Administration (TGA) has recalled four more batches ofSanofi-Aventis’s anticoagulant Clexane (enoxaparin), following detection of over-sulphated chondroitin sulphate (OCSC). Recalled doses include three batches of Clexane 8mg – batch numbers 08012, 08012A and 08014 – and one batch of Clexane 100mg, batch number 01010. The recall follows seven previous batches also recalled earlier this year. Patients prescribed Clexane are advised to check with their doctor or pharmacist that their supply is not affected by the recall. Appropriate alternative anticoagulants for prescription include Fragmin (dalteparin sodium), unfractionated heparin or oral anticoagulants. OCSC has been associated with severe adverse reactions in the US and Europe; to date, there have been no reports in Australia.
You may also be interested in...
The Indian pharmaceutical sector is recognised for its entrepreneurial spirit. Many companies have crafted successful business strategies by offering API manufacturing, drug discovery, CRAMS and other services to global pharmaceutical customers. Others market their products overseas while leveraging growth opportunities on their home turf. The following five domestic companies are well worth watching in 2011.
The Swedish biotech firm Active Biotech has appointed Dr Helén Tuvesson as its new chief scientific officer, effective 1 April. Dr Tuvesson has been with the company since 1998, working in preclinical development, R&D management and most recently within the senior management team. She will report to president and CEO Tomas Leanderson.
Affimed Therapeutics (Germany) has appointed Dr Adi Hoess as its new chief commercial officer. Effective immediately, Mr Hoess will focus on commercial and strategic management and business development, complimenting his previous senior management and business development roles at Jenowis, Carl Zeiss Jena, MorphoSys and Jerini. His appointment also coincides with the continued development of the company's lead product candidate, AFM13, for Hodgkin's lymphoma, which entered a Phase I clinical trial last November (scripintelligence.com, 15 November 2010).